Wataru Okamoto - My portal

Profile Information

Affiliation: -

J-GLOBAL ID: 201801010423557234
researchmap Member ID: B000306993

Papers

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.

Harada K, Okamoto W, Mimaki S, Kawamoto Y, Bando H, Yamashita R, Yuki S, Yoshino T, Komatsu Y, Ohtsu A, Sakamoto N, Tsuchihara K

BMC cancer, 19(1) 255-255, Mar, 2019 Peer-reviewed
Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.

Taniguchi H, Okamoto W, Muro K, Akagi K, Hara H, Nishina T, Kajiwara T, Denda T, Hironaka S, Kudo T, Satoh T, Yamanaka T, Abe Y, Fukushima Y, Yoshino T

Neoplasia (New York, N.Y.), 20(12) 1219-1226, Dec, 2018 Peer-reviewed
Utility of the Quasi-monomorphic Variation Range in Unresectable Metastatic Colorectal Cancer Patients.

Bando H, Okamoto W, Fukui T, Yamanaka T, Akagi K, Yoshino T

Cancer science, 109(11) 3411-3415, Aug, 2018 Peer-reviewed
Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study

Yoichi Naito, Hideaki Takahashi, Kohei Shitara, Wataru Okamoto, Hideaki Bando, Takeshi Kuwata, Yasutoshi Kuboki, Shingo Matsumoto, Izumi Miki, Takeharu Yamanaka, Atsushi Watanabe, Motohiro Kojima

Japanese Journal of Clinical Oncology, 48(6) 559-564, Jun 1, 2018 Peer-reviewed
Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer

Kentaro Sawada, Yoshiaki Nakamura, Takeharu Yamanaka, Yasutoshi Kuboki, Daisuke Yamaguchi, Satoshi Yuki, Takayuki Yoshino, Yoshito Komatsu, Naoya Sakamoto, Wataru Okamoto, Satoshi Fujii

Clinical Colorectal Cancer, 17(3) 198-205, 2018 Peer-reviewed
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

Yasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki, Kentaro Yamazaki, Kohei Shitara, Wataru Okamoto, Takeshi Kajiwara, Toshihiko Matsumoto, Takahiro Tsushima, Nobuo Mochizuki, Shogo Nomura, Toshihiko Doi, Akihiro Sato, Atsushi Ohtsu, Takayuki Yoshino

LANCET ONCOLOGY, 18(9) 1172-1181, Sep, 2017 Peer-reviewed
Current status and future perspectives of SCRUM-Japan

Atsushi Ohtsu, Koichi Goto, Takayuki Yoshino, Wataru Okamoto, Katsuya Tsuchihara

Japanese Journal of Cancer and Chemotherapy, 44(8) 621-626, Aug 1, 2017 Peer-reviewed
Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib

Ayako Doi, Yasutoshi Kuboki, Kohei Shitara, Shota Fukuoka, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino

CLINICAL COLORECTAL CANCER, 16(2) E109-E113, Jun, 2017 Peer-reviewed
Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer

Shota Fukuoka, Kohei Shitara, Masaaki Noguchi, Akihito Kawazoe, Yasutoshi Kuboki, Hedeaki Bando, Wataru Okamoto, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino

CLINICAL COLORECTAL CANCER, 16(2) E39-E44, Jun, 2017 Peer-reviewed
Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials

Yoshiaki Nagatani, Kohei Shitara, Hideaki Bando, Yasutoshi Kuboki, Wataru Okamoto, Takashi Kojima, Takayuki Yoshino, Toshirou Nishida, Atushi Ohtsu, Toshihiko Doi

BMC CANCER, 16(1) 889, Nov, 2016 Peer-reviewed
Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution

Daisuke Kotani, Kohei Shitara, Akihito Kawazoe, Shota Fukuoka, Yasutoshi Kuboki, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino

CLINICAL COLORECTAL CANCER, 15(3) E109-E115, Sep, 2016 Peer-reviewed
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors

Akiyoshi Kasuga, Kazuhiko Nakagawa, Fumio Nagashima, Toshio Shimizu, Daisuke Naruge, Shinichi Nishina, Hiroshi Kitamura, Takayasu Kurata, Atsuko Takasu, Yasuhito Fujisaka, Wataru Okamoto, Yuichiro Nishimura, Akihira Mukaiyama, Hideki Matsushita, Junji Furuse

INVESTIGATIONAL NEW DRUGS, 33(5) 1058-1067, Oct, 2015 Peer-reviewed
Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience

Akihito Kawazoe, Kohei Shitara, Shota Fukuoka, Masaaki Noguchi, Yasutoshi Kuboki, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Nozomu Fuse, Takayuki Yoshino, Atsushi Ohtsu, Toshihiko Doi

INVESTIGATIONAL NEW DRUGS, 33(3) 664-670, Jun, 2015 Peer-reviewed
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

Akihito Kawazoe, Kohei Shitara, Shota Fukuoka, Yasutoshi Kuboki, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Nozomu Fuse, Takeharu Yamanaka, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino

BMC CANCER, 15 258, Apr, 2015 Peer-reviewed
Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study

Takayuki Yoshino, Kei Muro, Kensei Yamaguchi, Tomohiro Nishina, Tadamichi Denda, Toshihiro Kudo, Wataru Okamoto, Hiroya Taniguchi, Kiwamu Akagi, Takeshi Kajiwara, Shuichi Hironaka, Taroh Satoh

EBIOMEDICINE, 2(4) 317-323, Apr, 2015 Peer-reviewed
Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer

Takayasu Kurata, Junji Tsurutani, Yasuhito Fujisaka, Wataru Okamoto, Hidetoshi Hayashi, Hisato Kawakami, Eisei Shin, Nobuya Hayashi, Kazuhiko Nakagawa

INVESTIGATIONAL NEW DRUGS, 32(5) 946-954, Oct, 2014 Peer-reviewed
Targeting MET Amplification as a New Oncogenic Driver

Hisato Kawakami, Isamu Okamoto, Wataru Okamoto, Junko Tanizaki, Kazuhiko Nakagawa, Kazuto Nishio

CANCERS, 6(3) 1540-1552, Sep, 2014 Peer-reviewed
A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors

Wataru Okamoto, Takayuki Yoshino, Toshiaki Takahashi, Isamu Okamoto, Shinya Ueda, Asuka Tsuya, Narikazu Boku, Kazuto Nishio, Masahiro Fukuoka, Nobuyuki Yamamoto, Kazuhiko Nakagawa

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 72(5) 1063-1071, Nov, 2013 Peer-reviewed
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

Hidetoshi Hayashi, Junji Tsurutani, Taro Satoh, Norikazu Masuda, Wataru Okamoto, Ryotaro Morinaga, Masaaki Terashima, Masaki Miyazaki, Isamu Okamoto, Yukihiro Nishida, Shusei Tominaga, Yukihiko Tokunaga, Masahide Yamaguchi, Junichi Sakamoto, Takahiro Nakayama, Kazuhiko Nakagawa

BREAST CANCER, 20(2) 131-136, Apr, 2013 Peer-reviewed
MET amplification as a potential therapeutic target in gastric cancer

Hisato Kawakami, Isamu Okamoto, Tokuzo Arao, Wataru Okamoto, Kazuko Matsumoto, Hirokazu Taniguchi, Kiyoko Kuwata, Haruka Yamaguchi, Kazuto Nishio, Kazuhiko Nakagawa, Yasuhide Yamada

ONCOTARGET, 4(1) 9-17, Jan, 2013 Peer-reviewed

Misc.

129

Construction of Clinico‐Genomic Database

岡本渉

Progress in Medicine, 38(9) 987‐991, Sep 10, 2018
Utilization of Patient Registry for development of anti‐cancer drugs; from a standpoint of academia: SCRUM‐Japan Registry.

岡本渉

月刊腫瘍内科, 22(2) 234‐237, Aug 28, 2018
HER2陽性大腸癌に対する国際協調診断基準の策定と新たなNGS利用の展望

藤井誠志, MAGLIOCCO Anthony, VALTORTA Emanuele, 澤田憲太郎, 中村能章, 岡本渉, 土原一哉, 吉野孝之

日本病理学会会誌, 107(1) 301, Apr 26, 2018
多施設共同スクリーニングプロジェクト(SCRUM‐Japan)における病理医の意義と期待される役割

岡本渉

日本病理学会会誌, 107(1) 197, Apr 26, 2018
【Precision medicineをめざした胆道・膵悪性腫瘍ゲノム医療の最前線】膵癌・胆道癌に対するクリニカルシーケンス SCRUM-Japanの取り組み

大場彬博, 森実千種, 岡本渉, 吉野孝之

胆と膵, 39(4) 343-347, Apr, 2018
新たな標準治療確立と実践のための病理の貢献多施設共同スクリーニングプロジェクト(SCRUM-Japan)における病理医の意義と期待される役割

岡本渉

日本病理学会会誌, 107(1) 197-197, Apr, 2018
大腸がん化学療法これまでの進歩とこれからの進化へ向けての挑戦

岡本渉

神奈川医学会雑誌, 45(1) 25-25, Jan, 2018
がんゲノム医療の現状と今後の展望産学連携全国がんゲノムスクリーニング「SCRUM-Japan」について

岡本渉

国立病院総合医学会講演抄録集, 71回 182-182, Nov, 2017
がん領域におけるPrecision Medicineはどこまで進んだか?―臨床腫瘍医に求められる新たなスキル―希少フラクション(稀少がん)治療開発における疾患レジストリの意義

岡本渉

月刊腫瘍内科, 20(4) 290‐292, Oct 28, 2017
大腸癌化学療法のトピックス海外学会における大腸癌領域のトピックス

岡本渉

大腸がんperspective, 3(4) 302-306, Oct, 2017
RASKET-Bの臨床的検証研究結腸直腸癌におけるRASとBRAF遺伝子変異に関する複数の検査用キット(A clinical validation study of RASKET-B: A multiple detection kit for RAS and BRAF gene mutations in colorectal cancer)

工藤敏啓, 佐藤太郎, 岡本渉, 室圭, 谷口浩也, 赤木究, 原浩樹, 仁科智裕, 梶原猛史, 傳田忠道, 廣中秀一, 吉野孝之

日本癌治療学会学術集会抄録集, 55回 IS6-6, Oct, 2017
【リアルワールドデータの活用と課題について】がん医薬品開発を目指したSCRUM-Japanレジストリの活用

大津敦, 岡本渉, 布施望, 青柳吉博, 土原一哉

レギュラトリーサイエンス学会誌, 7(3) 205-214, Sep, 2017
Current Status and Future Perspectives of SCRUM‐Japan

大津敦, 後藤功一, 吉野孝之, 岡本渉, 土原一哉

癌と化学療法, 44(8) 621‐626, Aug 15, 2017
患者レジストリ―ジャパンイニシアチブ―

岡本渉

月刊腫瘍内科, 19(5) 618‐620, May 28, 2017
Patient registry : Japan initiative

岡本渉

腫瘍内科 = Clinical oncology, 19(5) 618-620, May, 2017
【Precision Medicine】 SCRUM-Japanの現状

岡本渉, 後藤功一, 吉野孝之

がん分子標的治療, 15(1) 38-41, Mar, 2017
【これだけは押さえておきたいがん化学療法の薬抗がん剤・ホルモン剤・分子標的薬・支持療法薬はや調べノート2017・2018年版】分子標的薬 Bcr-Abl ダサチニブ水和物

岡本渉, 中川和彦

プロフェッショナルがんナーシング, (2017別冊) 26-27, Feb, 2017
新規技術が創り出す肝疾患診療のスペクタクル診断への応用 NGSを使った網羅的治療ターゲットの検索と治療への応用―SCRUM‐Japan/GI‐SCREEN‐Japanの試み―

岡本渉, 岡本渉, 吉野孝之

肝胆膵, 73(5) 699‐702, Nov 28, 2016
【新規技術が創り出す肝疾患診療のスペクタクル】診断への応用 NGSを使った網羅的治療ターゲットの検索と治療への応用 SCRUM-Japan/GI-SCREEN-Japanの試み

岡本渉, 吉野孝之

肝・胆・膵, 73(5) 699-702, Nov, 2016
大腸癌update III.基礎的研究分子生物学プロファイルと臨床情報の統合~SCRUM‐Japanの取り組み~

岡本渉, 吉野孝之

日本臨床, 74(11) 1812‐1817, Nov 1, 2016